Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

Moderna Stock (MRNA) Opinions on FDA Flu Vaccine Review - Quiver Quantitative

🦠 Moderna stock rallies amid anticipation of an FDA flu vaccine review decision expected in August.

🏛️ Institutional investors like Fidelity and BNP Paribas have increased their stakes, while Goldman Sachs raised its price target.

📉 The stock has rebounded from lows near $12 to around $53 after previously trading near $500.

📈 Technical indicators show resilience with RSI rising above 50 as shares test overhead resistance at $65-$90.

💬 Investors remain divided on the efficacy of mRNA flu shots and the resolution of ongoing patent disputes.

📉 Moderna holds the highest short interest in the S&P 500 despite reporting 10% revenue growth guidance.

🔐 Bulls anticipate patent resolutions could act as a catalyst for the stock's future performance.

👥 Company insiders have executed four trades over the past six months, all of which were sales.

🏦 Institutional investors have added shares to their portfolios while reducing positions at other firms in recent quarters.

📊 Analyst sentiment is mixed with two buy ratings issued against three sell ratings in recent months.

💰 Thirteen analysts have provided price targets for Moderna over the last six months.

🎯 The median analyst price target for Moderna stands at $30.0, below current trading levels.

Bullish Signals
  • The FDA expedited review for Moderna's flu vaccine decision is slated for August, fueling significant optimism among investors.
  • Institutional investors including Fidelity and BNP Paribas have boosted their stakes in the stock.
  • Goldman Sachs has lifted its price target for Moderna's shares.
  • Moderna's recent stock performance shows resilience by trading above key weekly moving average supports near $46-$50.
  • Despite a drop from nearly $500 to sub-$12 lows, the stock has bounced back to around $53 and tests overhead resistance at $65-$90.
  • Moderna provided revenue growth guidance showing a positive trajectory for the business.
Risk Factors
  • Moderna insiders have sold the stock 4 times over the past 6 months with zero purchases, indicating a lack of internal confidence.
  • Institutional investors are net reducing their positions in Moderna's recent quarter, with 318 decreasing stakes against only 261 additions.
  • Short interest remains extremely high at 10%, reflecting persistent market doubts about the company despite revenue growth guidance.
  • Critics question the efficacy of Moderna's mRNA flu shot and cite ongoing patent disputes as significant risks.
  • Wall Street analyst sentiment is mixed to bearish, with 3 firms issuing sell ratings compared to only 2 buy ratings recently.
  • The median analyst price target of $30.0 suggests significant downside potential from the current price level around $53.
Full Analysis
Social media discussions around Moderna have intensified as investors await an FDA expedited review of its flu vaccine scheduled for August, creating renewed optimism about the biotechnology company's prospects. Institutional investors are responding to this development with notable activity, including increased stakes from major firms like Fidelity and BNP Paribas, alongside Goldman Sachs raising its price target on the stock. These developments have helped propel Moderna shares significantly higher relative to their early 2026 levels, transforming a once dismissed "one-hit wonder" into one of the S&P 500's top performers, even as the stock trades at a fraction of its historical peak following a dramatic decline from nearly $500 to lows below $12. From a technical perspective, traders are observing Moderna's stock respecting key weekly moving average supports within the $46-$50 range, accompanied by recent green candle formations and an RSI climbing above 50 on rising volume. While shares have rebounded to around $53, market participants are debating whether the current pattern forms a bull flag or risks rolling over if prices break below critical levels. Overhead resistance at $65-$90 continues to test these bullish sentiments as the stock navigates a potential pivot point. Despite the positive momentum and 10% revenue growth guidance, sentiment remains deeply divided due to high short interest that leads Moderna among S&P 500 names. Critics continue to question the efficacy of an mRNA flu shot and cite ongoing patent disputes as significant headwinds, whereas bulls view potential patent resolutions as key catalysts for future growth. Insider trading data reveals mixed signals from company executives, with four sales recorded on the open market over the past six months against zero purchases, while institutional holders show a slight net outflow of 57 shares between those who added positions and those who decreased them in the last quarter. Wall Street analyst consensus remains cautious, with recent reports including two buy ratings and three sell ratings, while a median price target set by 13 analysts stands at $30.0, suggesting divergent views on the stock's valuation potential amidst ongoing regulatory reviews and patent developments.